<< Read Full Article
<< Read Full Article
Introgen Critically Hurt by FDA Advexin Snub
Introgen Therapeutics (INGN Quote) has fallen again -- and this time, the beleaguered drug company isn't likely to get back up.
The Food and Drug Administration refused to accept an approval application from Introgen for its gene therapy cancer drug Advexin, the company announced Tuesday.
Introgen shares plummeted 34.4% to 61 cents in recent trading. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.68 | 1,109.24 | 2,185.03 | 33.23 |
Oil *
77.83
|
|
DOWN
18.90
|
UP
0.38
|
UP
9.22
|
UP
0.48
|
10 Yr
3.32%
SPDR Gold
119.18
|
|
-0.18%
|
+0.03%
|
+0.42%
|
+1.47%
|
Data delayed 20 minutes |
Connect with TheStreet